Pexiganan

The most clinically advanced antimicrobial peptide ever made—tested in 835 patients, matched an existing antibiotic, and denied FDA approval because matching was not enough

Pexiganan holds a unique and bittersweet position in pharmaceutical history. It is the only antimicrobial peptide to complete Phase III clinical trials—the final stage before FDA approval. The topical cream cleared infected diabetic foot ulcers as effectively as a standard oral antibiotic. The safety profile was clean. The mechanism—membrane disruption—was confirmed in clinical isolates from actual patients. Every box was checked except one: superiority.

The FDA's position was that a new drug class—antimicrobial peptides had never been approved for human use—needed to demonstrate that it was better than existing treatments, not merely equivalent. The rationale was sound: why should physicians switch to a novel class if it offers no improvement? But the consequence was devastating for the entire AMP field. The compound that proved the concept viable became the cautionary tale that discouraged investment in every subsequent AMP drug candidate.

A second company, Dipexium Pharmaceuticals, acquired the rights and attempted new Phase III trials (the LEADER program) around 2016. Those trials also failed to meet primary endpoints. Development was permanently discontinued. This article examines the full evidence record of the most instructive failure in antimicrobial drug development.

Quick Facts: Pexiganan at a Glance

What Is Pexiganan?

Pronunciation: pex-IG-ah-nan

Most drug development stories end in failure. Pexiganan's failure is different—not because the science failed, but because the science succeeded and the market did not accommodate it. Understanding pexiganan requires understanding both the biology and the regulatory logic that determined its fate.

Designed from Nature

Pexiganan (MSI-78) was engineered from magainin 2—the antimicrobial peptide Michael Zasloff discovered in African clawed frog skin in 1987. Zasloff's company, Magainin Pharmaceuticals, systematically modified the parent peptide's sequence to increase potency while maintaining selectivity. The changes were straightforward: more lysine residues (increasing positive charge for stronger bacterial membrane binding) and enhanced amphipathicity (improving membrane insertion). The result was a 22-amino-acid peptide that was 2–4 times more potent than its parent against clinical bacterial isolates.

The Drug Candidate

Pexiganan was formulated as a topical 1% cream (proposed brand name: Locilex) for the treatment of mildly infected diabetic foot ulcers—a condition that affects approximately 15% of diabetic patients and is a leading cause of non-traumatic limb amputation. The topical route was chosen for practical reasons: it avoids systemic exposure (and associated safety concerns) and targets the peptide directly to the infection site.

Origins and Discovery

From Zasloff's Lab to Magainin Pharmaceuticals

The magainin-to-pexiganan pipeline represents one of the clearest examples of rational drug design from a natural product lead. After the 1987 discovery, Zasloff founded Magainin Pharmaceuticals with the explicit goal of developing antimicrobial peptides as clinical drugs.

The optimization process followed classical medicinal chemistry principles applied to peptides: systematic amino acid substitutions to identify positions critical for activity, selectivity, and stability. The design rationale was published and the structure-activity relationships were transparent—a contrast to the proprietary secrecy of most pharmaceutical development.

Phase III: The Pivotal Trials (1999)

Magainin Pharmaceuticals sponsored two Phase III trials in patients with mildly infected diabetic foot ulcers:

• Design: Randomized, controlled, open-label
• Enrollment: 835 outpatients across both trials
• Treatment arms: Topical pexiganan 1% cream (twice daily) vs. oral ofloxacin (standard of care)
• Primary endpoint: Clinical cure (resolution of infection)
• Microbiology: 2,515 bacterial isolates were recovered and tested (Ge et al., 1999; PMID 10529881)

The results showed clinical cure rates that were comparable between groups. Pexiganan was well-tolerated—mild local application-site reactions were the primary adverse events. No systemic adverse effects were attributed to the peptide.

The FDA Decision

In 1999, the FDA's Anti-Infective Drugs Advisory Committee reviewed the pexiganan NDA and recommended against approval. The reasoning: pexiganan demonstrated non-inferiority to ofloxacin, but the FDA required superiority for a first-in-class antimicrobial peptide. The committee's logic was that a novel drug class—with unknown long-term implications—needed to offer a clear clinical advantage to justify the risk of introducing it into clinical practice.

The Second Attempt: Dipexium and LEADER

After Magainin Pharmaceuticals was dissolved, the pexiganan intellectual property passed through several owners before reaching Dipexium Pharmaceuticals. Dipexium launched the LEADER (Locilex Enhancement and Assessment of Diabetic Extremity Repair) clinical program around 2016—a new Phase III trial designed to address the FDA's original objections.

The LEADER trials also failed to meet primary endpoints. Dipexium discontinued development. Pexiganan, as a pharmaceutical product, was dead.

Mechanism of Action

Optimized Magainin Mechanism

Pexiganan works through the same fundamental mechanism as its parent magainin 2: alpha-helical membrane permeabilization. The engineering changes—increased cationicity and enhanced amphipathicity—lower the threshold concentration needed for membrane disruption, resulting in lower MICs against clinical isolates.

Step 1: Binding. Pexiganan's elevated positive charge (+9 at physiological pH, compared to +4 for magainin 2) drives stronger electrostatic attraction to anionic bacterial membranes.

Step 2: Insertion. The optimized amphipathic helix inserts more efficiently into the lipid bilayer.

Step 3: Disruption. At lower peptide-to-lipid ratios than magainin 2, pexiganan causes membrane permeabilization, ion efflux, and cell death.

Broad-Spectrum Activity in Clinical Isolates

The Phase III microbiology data (Ge et al., 1999; PMID 10529881) demonstrated activity against the full range of pathogens recovered from diabetic foot ulcers: - S. aureus (including MRSA) - E. coli - P. aeruginosa - Enterococcus species - Proteus species - Klebsiella species - Anaerobic species

MIC₉₀ values were generally 16–64 μg/mL. No cross-resistance with conventional antibiotics was observed—isolates resistant to ofloxacin, ciprofloxacin, or cephalosporins remained susceptible to pexiganan.

Why No Cross-Resistance

Pexiganan targets the bacterial membrane—a fundamental structural component—rather than a specific enzyme or protein. Conventional antibiotic resistance mechanisms (beta-lactamase production, efflux pumps, target modification) do not affect pexiganan's mechanism. This absence of cross-resistance was one of the strongest arguments for approval and remains the most clinically relevant property of the compound.

Key Research Areas and Studies

Phase III Microbiology (Ge et al., 1999)

Ge et al. (PMID 10529881) analyzed 2,515 bacterial isolates recovered from the Phase III DFU patients—one of the largest antimicrobial susceptibility datasets ever generated for an antimicrobial peptide. The data confirmed broad-spectrum activity across all major DFU pathogens, including polymicrobial isolates. The absence of cross-resistance with fluoroquinolones, beta-lactams, and aminoglycosides was a significant finding.

In Vitro Characterization (Ge et al., 1999)

A companion study (PMID 10203487) provided comprehensive in vitro MIC data for pexiganan against a large panel of clinical isolates, establishing the antibacterial profile independently of the Phase III clinical context.

Structure and Mechanism (Gottler & Ramamoorthy, 2009)

Gottler and Ramamoorthy (PMC2726618) published a comprehensive review of pexiganan's structure, membrane orientation, mechanism, and function. Using solid-state NMR and molecular dynamics, they mapped the peptide's orientation within lipid bilayers—lying at approximately 86° relative to the bilayer normal in anionic membranes. This work provided atomic-level understanding of how pexiganan disrupts membranes.

The FDA Superiority Requirement

The FDA's decision is itself a significant study in regulatory science. The advisory committee transcript reveals the reasoning: for a novel mechanism class with no long-term safety track record, the committee required evidence of clear clinical advantage. Non-inferiority—demonstrating that pexiganan was "not worse than" ofloxacin—was insufficient to justify introducing a new drug class. This standard has been debated extensively in the antimicrobial drug development community.

Claims vs. Evidence

The Human Evidence Landscape

Pexiganan has the most extensive human evidence of any antimicrobial peptide ever developed.

Phase III — Diabetic Foot Ulcers (1999)

Trial Design. Two randomized, controlled, open-label, multicenter trials in outpatients with mildly infected (Wagner Grade 1–2) diabetic foot ulcers.

Enrollment. 835 patients total across both trials.

Treatment. Topical pexiganan 1% cream applied twice daily vs. oral ofloxacin 800 mg/day.

Primary Endpoint. Clinical cure—resolution of signs and symptoms of infection.

Results. Clinical cure rates were comparable between pexiganan and ofloxacin groups. The trials demonstrated non-inferiority.

Microbiology. 2,515 bacterial isolates were recovered and tested. Pexiganan demonstrated broad-spectrum in vitro activity against all recovered pathogens (Ge et al., 1999; PMID 10529881).

Safety. Well-tolerated. Mild local application-site reactions were the most common adverse events. No serious adverse events were attributed to pexiganan. No systemic absorption concerns with topical application.

Regulatory Outcome. FDA Anti-Infective Drugs Advisory Committee recommended against approval. Rationale: non-inferiority insufficient for a first-in-class agent. Superiority required.

LEADER Trials (~2016, Dipexium Pharmaceuticals)

Trial Design. Phase III trials designed to re-investigate pexiganan for mildly infected DFUs, with trial design modifications intended to address the FDA's original objections.

Results. Failed to meet primary endpoints. Specific failure points have not been fully disclosed in public literature.

Outcome. Dipexium discontinued development. No further clinical development is planned by any sponsor.

Summary of Human Evidence

Pexiganan is the only AMP with Phase III human data. The evidence demonstrates: (1) an AMP can be manufactured at pharmaceutical scale, (2) formulated as a stable topical product, (3) achieve clinical cure rates comparable to oral antibiotics for mild wound infections, and (4) be well-tolerated with a clean safety profile. The evidence does not demonstrate superiority over existing therapies—the gap that determined pexiganan's commercial fate.

Safety, Risks, and Limitations

Phase III Safety Data

The Phase III safety profile was favorable: - Local reactions: Mild application-site irritation was the most common adverse event. - Systemic effects: None attributed to pexiganan. Topical application minimizes systemic exposure. - Serious adverse events: None related to study drug. - No immunogenicity signal: No antibody formation against pexiganan was reported.

This represents the best safety data available for any antimicrobial peptide in humans.

Limitations of Safety Data

• All safety data is from topical use only. Injectable or systemic pexiganan safety is unknown.
• Trial populations were outpatients with mild infections—safety in more seriously ill patients is unknown.
• Duration of exposure was limited to treatment of a single infection episode. Long-term or repeated-use safety is unknown.

Resistance Concerns

No pexiganan resistance was observed in the 2,515 clinical isolates tested. The membrane-targeting mechanism provides a theoretical resistance barrier. However, laboratory studies with other antimicrobial peptides have shown that resistance can emerge under sustained selective pressure—the question is whether therapeutic use would create sufficient pressure.

Formulation Limitation

Pexiganan was developed exclusively as a topical cream. The peptide is susceptible to proteolytic degradation, making systemic administration impractical without significant formulation engineering. This limits potential clinical applications to surface infections.

Legal and Regulatory Status

FDA Status

Not approved. NDA denied by FDA Anti-Infective Drugs Advisory Committee in 1999 (non-inferiority insufficient). Second Phase III program (LEADER) failed to meet primary endpoints (~2016). No active regulatory path.

Development History

• Magainin Pharmaceuticals: Original developer. Filed NDA 1999. Denied. Company eventually dissolved.
• Dipexium Pharmaceuticals: Acquired rights. Conducted LEADER trials. Failed. Discontinued development.
• Current status: No active sponsor. No IND. Development abandoned.

WADA Status

Not on the Prohibited List. Not relevant to athletic performance.

Intellectual Property

Patents held by Magainin Pharmaceuticals and subsequently Dipexium have expired or are expiring. The compound is effectively in the public domain, but the absence of a commercial sponsor makes this moot.

Research Protocols and Formulation Considerations

Pharmaceutical-Grade Formulation

Pexiganan was formulated as MSI-78 Cream (1% pexiganan acetate in a cream base) for clinical use. This represents the most advanced pharmaceutical formulation ever achieved for an antimicrobial peptide. The cream was stable, well-tolerated, and delivered active peptide to wound surfaces.

Synthesis

Pexiganan is a linear 22-amino-acid peptide with no disulfide bonds or post-translational modifications. It is synthesized by standard solid-phase peptide synthesis (SPPS). At pharmaceutical scale, the manufacturing cost was manageable—another advantage over structurally complex peptide drugs.

Research Access

Pexiganan is available from research peptide suppliers at standard research-grade purity. No pharmaceutical-grade product is currently manufactured.

Dosing in Published Research

The following table summarizes dosing protocols for Pexiganan as reported in published clinical and preclinical research. These reflect study designs, not treatment recommendations.

Phase III Clinical Dosing

The only human dosing data comes from the Phase III trials: - Formulation: Topical 1% cream (10 mg/mL pexiganan acetate) - Application: Applied directly to infected diabetic foot ulcer and surrounding area - Frequency: Twice daily - Duration: Until clinical resolution (trial-specific protocols)

In Vitro Pharmacology

MIC₉₀ values from Phase III clinical isolates (Ge et al., 1999; PMID 10529881): 16–64 μg/mL against the major DFU pathogens. These values are achievable at the wound surface with a 1% topical formulation.

No Systemic Dosing Data

Pexiganan was never tested by injection, oral, or any systemic route. Pharmacokinetic data (absorption, distribution, metabolism, elimination) is limited to demonstrating that topical application does not result in measurable systemic absorption.

Dosing in Self-Experimentation Communities

Pexiganan is not available from peptide vendors serving the biohacker community. It was developed as a pharmaceutical product and has been discontinued. No self-experimentation community discusses pexiganan. It is available only as a research-grade reagent from laboratory suppliers.

Combination Stacks

Research into Pexiganan combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.

If you are considering combining Pexiganan with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.

style="color:#0F4C5C;font-size:28px;font-weight:700;margin:48px 0 16px 0;line-height:1.2">Frequently Asked Questions

Summary of Key Findings

Pexiganan (MSI-78) is the most clinically tested antimicrobial peptide in history and the most instructive case study in AMP drug development. The Phase III program in 835 patients with infected diabetic foot ulcers demonstrated clinical efficacy comparable to oral ofloxacin, broad-spectrum activity against 2,515 clinical isolates (including drug-resistant organisms), a clean safety profile, and no cross-resistance with conventional antibiotics.

The compound was denied FDA approval in 1999 because non-inferiority was insufficient for a first-in-class agent. A second development attempt (LEADER trials, ~2016) also failed. Development has been permanently discontinued.

Pexiganan's legacy is dual: it proved that antimicrobial peptides can work as drugs in human patients, and it demonstrated that biological proof-of-concept is necessary but not sufficient for market success. The compound stands as both the high-water mark of AMP clinical development and the event that chilled investment in the entire field.

Verdict Recapitulation

The Eyes Open verdict for a Tier 2 compound reflects pexiganan's unique position: the clinical evidence is real and positive, but the drug has been abandoned after two regulatory failures. There is no path forward. The evidence shows what pexiganan can do; the market has determined it will not do it. Eyes Open—the compound is worth understanding as the most important data point in AMP drug development history, not as a therapeutic option.

For readers considering Pexiganan, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.

Where to Source Pexiganan

Further Reading and Resources

If you want to go deeper on Pexiganan, the evidence landscape for antimicrobial peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

ON PEPTIDINGS

• Antimicrobial Research Hub — Overview of all compounds in this cluster
• Reconstitution Guide — How to properly prepare injectable peptides
• Storage and Handling Guide — Proper storage to maintain peptide stability
• About Peptidings — Our editorial methodology and evidence framework

EXTERNAL RESOURCES

• PubMed: Pexiganan — All indexed publications
• ClinicalTrials.gov — Active and completed trials

Selected References and Key Studies

1. Ge, Y., et al. (1999). "In vitro susceptibility to pexiganan of bacteria isolated from infected diabetic foot ulcers." Diagn Microbiol Infect Dis, 35(1), 45–53. PMID 10529881
2. Ge, Y., et al. (1999). "In vitro antibacterial properties of pexiganan, an analog of magainin." Antimicrob Agents Chemother, 43(4), 782–788. PMID 10203487
3. Gottler, L. M. & Ramamoorthy, A. (2009). "Structure, membrane orientation, mechanism, and function of pexiganan—a highly potent antimicrobial peptide designed from magainin." Biochim Biophys Acta, 1788(8), 1680–1686. PMC2726618
4. Zasloff, M. (1987). "Magainins, a class of antimicrobial peptides from Xenopus skin." Proc Natl Acad Sci USA, 84(15), 5449–5453. PMID 3299702